They are an Indian multinational pharmaceutical company located in Hyderabad, Telangana, India. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited.
Company profile
Ticker
RDY
Exchange
Website
CEO
G. Prasad
Employees
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
43505116
RDY stock data
Latest filings (excl ownership)
6-K
Current report (foreign)
27 Mar 24
6-K
Current report (foreign)
22 Mar 24
6-K
Current report (foreign)
22 Mar 24
6-K
Current report (foreign)
19 Mar 24
6-K
Current report (foreign)
15 Mar 24
6-K
Current report (foreign)
14 Mar 24
6-K
Current report (foreign)
14 Mar 24
6-K
Current report (foreign)
13 Mar 24
6-K
Current report (foreign)
12 Mar 24
6-K
Current report (foreign)
4 Mar 24
Transcripts
RDY
Earnings call transcript
2023 Q2
28 Oct 22
RDY
Earnings call transcript
2023 Q1
31 Jul 22
RDY
Earnings call transcript
2022 Q4
19 May 22
RDY
Earnings call transcript
2022 Q3
28 Jan 22
RDY
Earnings call transcript
2021 Q1
27 Jul 21
RDY
Earnings call transcript
2021 Q4
14 May 21
RDY
Earnings call transcript
2021 Q3
30 Jan 21
RDY
Earnings call transcript
2021 Q2
28 Oct 20
Latest ownership filings
144
Notice of proposed sale of securities
27 Oct 23
144
Notice of proposed sale of securities
27 Jul 23
SC 13D/A
Dr. Reddy's Holdings Ltd
2 May 22
SC 13G/A
MITSUBISHI UFJ FINANCIAL GROUP INC
2 Feb 21
SC 13G/A
BlackRock Inc.
9 Apr 20
SC 13G
Beneficial ownership report
13 Feb 20
SC 13G
Beneficial ownership report
7 Feb 20
SC 13G/A
Beneficial ownership report (amended)
10 Dec 19
SC 13G
DR Reddys Laboratories LTD
9 Sep 19
SC 13G
Beneficial ownership report
8 Feb 19
Financial summary
Quarter (USD) | Mar 23 | Mar 22 | Mar 21 | Mar 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Mar 23 | Mar 22 | Mar 21 | Mar 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q3 2023
39.7% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 206 |
Opened positions | 33 |
Closed positions | 15 |
Increased positions | 85 |
Reduced positions | 57 |
13F shares | Current |
---|---|
Total value | 1.43 tn |
Total shares | 66.22 mm |
Total puts | 1.00 k |
Total calls | 34.80 k |
Total put/call ratio | 0.0 |
Largest owners | Shares | Value |
---|---|---|
Dr. Reddy's | 44.46 mm | $2.40 bn |
BLK Blackrock | 2.48 mm | $166.12 bn |
RY Royal Bank Of Canada | 2.15 mm | $143.59 bn |
GS Goldman Sachs | 1.98 mm | $132.24 bn |
Renaissance Technologies | 1.84 mm | $122.67 bn |
Robeco Institutional Asset Management B.V. | 1.67 mm | $111.88 bn |
Vanguard | 1.05 mm | $70.09 bn |
Dimensional Fund Advisors | 827.49 k | $55.31 bn |
MS Morgan Stanley | 736.80 k | $49.27 bn |
GQG Partners | 722.45 k | $48.31 bn |
News
Global Access to Weight-Loss Treatments: Indian Pharma Giants Eye Affordable Wegovy Alternatives Amid Rising Demand
22 Feb 24
Dr Reddy's Laboratories: Q3 Earnings Insights
30 Jan 24
Dr Reddy's Laboratories Q3 EPS $0.99 Beats $0.79 Estimate, Sales $866.64M Beat $825.86M Estimate
30 Jan 24
Barclays Maintains Overweight on Dr Reddy's Laboratories, Raises Price Target to $80
29 Jan 24
Dr Reddy's Laboratories Issues Response Regarding A News Item Published In "Sky News" On January 16, 2024, With The Heading "Indian Pharma Group Dr Reddy's Eyes Swoop On Nicotinell"; Says "The Company Does Not Comment On Market Speculations"
16 Jan 24
Press releases
Pharmazz Inc. and Dr. Reddy's Laboratories have entered into a licensing agreement to market Centhaquine (Lyfaquin) as a resuscitative agent for hypovolemic shock in India
22 Mar 24
Dr. Reddy's Laboratories launches Versavo® (bevacizumab) in the UK
19 Mar 24
Dr. Reddy's Q3 & 9M FY24 Financial Results
31 Jan 24
Dr. Reddy's Announces the Acquisition of MenoLabs®, a Leading Women's Health and Dietary Supplements Portfolio of Brands
3 Jan 24